A New Treatment for Complex Wounds

A flowable wound matrix helps patients with venous leg ulcers (VLCs) and diabetic foot ulcers achieve closure of difficult, irregular wounds that could lead to amputation.

The Integra Flowable Wound Matrix is indicated for the management of wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled or undermined wounds, surgical wounds, trauma wounds, and draining wounds. Based on collagen-glycosaminoglycan technology the matrix provides an alternative to filling deep soft tissue or tunneling wounds in diabetic foot and venous leg ulcers. The matrix is hydrated with saline and applied in difficult to access wound sites and tunneled wounds, providing a scaffold for cellular invasion and capillary growth. The device is supplied in sterile, single use kits containing one syringe with granular collagen, one empty sterile syringe, one luer lock connector, and one flexible injector.

"This flowable form of the matrix maintains and provides a scaffold for rapid in-growth of new cells, vascularization, and tissue deposition,” said John Steinberg, M.D., an assistant professor in the department of plastic surgery at the Georgetown University School of Medicine (Washington, DC, USA) and a member of the limb salvage team. "Integra has made good use of its proven regenerative technologies to provide an intimate contact with the wound margins, a helpful new treatment option in the care and healing of complex wounds.”

The Integra Flowable Wound Matrix is manufactured by Integra LifeSciences (Plainsboro, NJ, USA) and has been approved by the U.S. Food and Drug Administration (FDA).

Approximately 500,000 adults in the United States alone seek treatment for venous leg ulcers (VLUs) annually; a figure that likely underestimates the true prevalence of VLUs because many individuals fail to seek medical care for recurrent ulcers.


Related Links:
Georgetown University School of Medicine
Integra LifeSciences